Understanding Influenza-associated HLH

Influenza-associated HLH (hemophagocytic lymphohistiocytosis) is an under-recognized but life-threatening hyper-inflammatory condition. While viral infections frequently trigger HLH, clinicians often overlook influenza as a primary driver. Recent systematic reviews indicate that this condition affects a wide age range, from infants to the elderly. Specifically, Influenza A, particularly the H1N1 strain, is responsible for over 90% of documented cases. Recognizing the clinical presentation early is vital for improving patient prognosis in acute settings.

Clinical Presentation and Diagnostic Markers

The clinical manifestation of this condition is often severe and multisystemic. According to pooled data, all patients present with fever. In addition, common laboratory findings include elevated ferritin levels in nearly 95% of cases and hemophagocytosis on biopsy in over 97%. Other frequent markers include thrombocytopenia, splenomegaly, and hypertriglyceridemia. Furthermore, nearly half of the patients exhibit leukopenia or anemia. Because these symptoms mimic severe sepsis or primary viral pneumonia, clinicians must maintain a high index of suspicion for Influenza-associated HLH when standard treatments fail.

Managing Influenza-associated HLH

Effective management requires a dual approach focusing on the underlying infection and the hyper-inflammatory response. Current therapeutic strategies typically involve antiviral therapy combined with HLH-directed treatments such as corticosteroids, intravenous immunoglobulin (IVIG), and etoposide. Data suggests that patients receiving both antiviral and HLH-directed therapies have a survival rate of 65.4%, compared to only 50% for those receiving either therapy alone. Consequently, early initiation of combined treatment is essential. Most patients require intensive care, highlighting the severity of this syndrome.

FAQs

What are the primary diagnostic markers for influenza-associated HLH?

The most common markers include persistent fever, highly elevated ferritin levels (above 94% of cases), hemophagocytosis on biopsy, and cytopenias such as thrombocytopenia and anemia.

Which influenza strain is most commonly linked to HLH?

Influenza A is the most frequent culprit, accounting for over 91% of cases, with the H1N1 subtype being the predominant strain identified in systematic reviews.

Does combined therapy improve survival rates?

Yes, clinical data indicates that combining antiviral therapy with HLH-directed treatments (like steroids or etoposide) increases the survival rate to approximately 65%, compared to 50% with monotherapy.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Balusu K et al. Influenza as a Less Commonly Recognized Cause of Hemophagocytic Lymphohistiocytosis: A Systematic Review of Case Reports and Case Series. Eur J Haematol. 2026 Jun 17. doi: 10.1111/ejh.70241. PMID: 42306884.

Henter JI et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.

Ramos-Casals M et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.